AbstrAct: Dynamic susceptibility contrastenhanced magnetic resonance imaging is routinely used to provide hemodynamic assessment of brain tumors as a diagnostic as well as a prognostic tool. Recently, it was shown that the relative cerebral blood volume (rCBV), obtained from the contrastenhancing as well as nonenhancing portion of glioblastoma (GBM), is strongly associated with overall survival. In this study, we aim to characterize the genomic cor relates (microRNA, messenger RNA, and protein) of this vascular parameter. This study aims to provide a comprehensive radiogenomic and radioproteomic characterization of the hemodynamic phenotype of GBM using publicly available imaging and genomic data from the Cancer Genome Atlas GBM cohort. Based on this analysis, we identified pathways associated with angiogenesis and tumor proliferation underlying this hemodynamic parameter in GBM.
Introduction
Glioblastoma (GBM) is a WHO grade IV tumor with an extre mely poor prognosis and a median survival of 12-15 months. Many imaging features are used to characterize GBM, such as structural magnetic resonance imaging (MRI), diffusion MRI, and perfusion MRI. 1 Several of these derived radiology based image features (denoted radiophenotypes) have shown asso ciation with the underlying genetics and biology of the tumor. 2 Identification of such noninvasive surrogates of clinical outcome and the associated molecular differences might point to a deeper understanding of the underlying disease state. 3, 4 Several studies [5] [6] [7] have demonstrated that imaging pheno types derived from MRI studies might have the potential to serve as noninvasive proxies of cancerassociated clinical out comes. In this regard, we follow up on recent studies based on dynamic susceptibility contrastenhanced MRI (DSC MRI) that identifies a hemodynamic parameter associated with overall survival. Specifically, these studies 5, 8 pointed to the association of rCBV max (maximum relative cerebral blood volume of the contrastenhancing component of GBM) and rCBV NER (rCBV in the nonenhancing region of the tumor) with patient survival.
The Cancer Genome Atlas (TCGA) 9 contains compre hensive genomic data (spanning expression, copy number, methylation, microRNA (miRNA), etc.). The Cancer Imaging Archive (TCIA) 10 is a publicly available repository of patient derived images across multiple modalities (singlephoton emission computed tomography, computed tomography, and MRI) and multiple tumor types in many of the patients who have corresponding molecular data in TCGA. Using genomic and imaging data from the TCGAGBM archive, we carried out a bioinformatics analysis to identify molecular correlates of imaging features associated with survival.
Based on the prognostic significance of the hemody namic parameter (rCBV max) value, we sought to examine the molecular correlates of rCBV max via differential expression analysis of messenger RNA (mRNA), miRNA, and protein levels. The intent was to identify molecular entities that are likely regulated across different layers of biological complexity: each modality (mRNA, miRNA, and protein) provides com plementary information about the biology of the process of GBM tumorigenesis. Thus, we decided to combine the sig nificantly associated genes (transcriptional correlate), miR NAs (posttranscriptional correlate), and proteins (signal Integrative Analysis of mRNA, microRNA, and Protein
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transduction correlate) to identify if there was a concordant biological process (or processes) that could be inferred when these three-omic modalities were combined. Combining entities found associated with tumor hemodynamic response across different biological layers has the potential to illuminate important regulatory processes.
For this purpose, patients were dichotomized based on median rCBV max value and then examined for differential expression of mRNA, miRNA, and protein levels. A molec ular examination of the two phenotypic groups reveals that genes and miRNAs related to the molecular process of angio genesis underlie this phenotypic transition between low and high rCBV max groups.
Materials and Methods
Ethics statement. All patients in this retrospective study had been previously deidentified by TCGA, a publicly avail able data set that contains no linkage to patient identifiers and is compliant with the Health Insurance Portability and Accountability Act; therefore, a waiver was obtained from the Henry Ford Hospital Institutional Review Board of Henry Ford Hospital, Detroit, MI. This research complied with the principles of the Declaration of Helsinki.
Patient population. Based on the availability of perfu sion (DSC) MRI image data from the TCIA and the corre sponding genomic expression from TCGA, 50 GBM cases were identified (19 females, 30 males, and 1 unknown). These cases were selected to ensure consistency in glioma history and treatment profile. Specifically, patients with untreated primary GBM were selected. Clinical data for this population were obtained from the cBioPortal for Can cer Genomics.
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Image features. Radiology annotations of the 50 GBM cases and their preoperative images (from TCIA) were obtai ned from the TCGA Glioma Phenotype Research Group. 10 This Health Insurance Portability and Accountability Act compliant retrospective study was approved by the Henry Ford Hospital Institutional Review Board (IRB #6381). Patients underwent DSC T2*weighted MR perfusion studies and had gene expression data available from TCGA. Fifteen cases were imaged in a 3 T scanner, while others were imaged in a 1.5 T scanner. rCBV max was measured from a region of interest of 10 × 10 voxels 5 placed on the hottestappearing tumor region based on qualitative perfusion maps.
Genomic features. Batchcorrected, Level 3 expression data for both mRNA (Affymetrix U133Av2 BI Platform: Affymetrix HT HG U133A) and miRNA (UNC Agilent Human miRNA 8x15K) were downloaded from the UT MD Anderson Genome Data Analysis Center Portal 12 version dated June 18, 2013. Protein expression from reversephase protein array (RPPA) was downloaded from the Cancer Pro teome Portal. 13 Fortyseven cases had miRNA and mRNA data available, whereas 15 cases had data for all three platforms. Instead of restricting our study to just the 15 common cases for differential expression analysis, we performed analysis of each platform separately and integrated the differential expression results subsequently via pathway analysis.
Defining classes based on median rCBV max . Based on the prior finding that rCBV max is associated with survival in a sta tistical significant manner, 5 we sought to examine the molecu lar correlates of rCBV max via differential expression analysis. Median rCBV max across the entire dataset was used to divide the study population into two groups.
Differential expression analysis between cutpoint-induced phenotype classes. Differential expression analysis for mRNA, miRNA, and protein was done to investigate molecular diffe rences between the median rCBV max induced phenotype groups. This was done using a twosided ttest to identify genes, miRNAs, and proteins that are differentially expressed between the two classes. Because of the exploratory nature of this study, no correction was performed for multiple hypothesis testing.
Functional analysis and integrative analysis. For relat ing differentially expressed miRNAs with differentially expressed mRNAs, the miRNA target filter feature (experimentally validated as well as high confidence sequence matches) is used within Ingenuity Pathway Analysis (IPA) software to find miRNAs that target the differentially expressed genes. Such integrative miRNA:mRNA analysis looks for target relationship (based on sequence affinity, using data bases like TargetScan) between miRNAs and the mRNAs derived from differential expression analysis. In addi tion, the miRNA target filter in IPA looks for concordant changes in expression, ie, anticorrelated expression changes in miRNA:mRNA abundance.
Integrative network analysis of mirNA, mrNA and protein 141 entities via Ingenuity Pathway network analysis. Core analysis and functional analysis were performed on the differentially expressed gene, protein, and miRNA lists. We explored both "Direct and Indirect Interactions" using "Experimentally Observed OR High Confidence Predictions" in the IPA knowledgebase. results differential expression programs between phenotypic classes reveal the role for cell proliferation and angiogenesisassociated pathways. The differential expression analysis procedure on the mRNA, protein, and miRNA data yields 326 genes, 76 miRNAs, and 8 proteins that are differentially expressed between these two phenotype classes. For complete ness, the ontological analysis of these genes, miRNAs, and proteins (using the IPA tool) is presented ( Table 1 ). The key pathways activated in this set are related to cellular develop ment, cellular proliferation, cell death, interleukin signaling, and inflammatory response. 14, 15 Integrated mirNA:mrNA analysis reveals multiple molecules underlying the transition of this perfusionassociated phenotype. We reasoned that combining the differentially expressed miRNAs and mRNAs might reveal a robust mechanism underlying the transition between the two phenotypic classes. Using the IPA tool, we combined the miRNA expression results with the mRNA expression results and found that eight differentially expressed miRNAs (miR 29b3p, miR495-3p, miR30c/30d, miR26a5p, miR296-5p, miR128-3p, miR144-3p, and miR214-3p) target several differentially expressed genes (including PTEN, COL15A1, SPARC, ANPEP, CBFB, STRN, and TMED10) while exhibiting concordant expression correlation (the expression levels of the mRNAs are anticorrelated with the miRNA expression levels).
Several of these miRNAs have been shown to play a key role in GBM. miR26a regulates PTEN and is observed to be amplified in highgrade gliomas in addition to promoting tumorigenesis. 16 miR29b has been shown to regulate invasion in GBM. 17 Examination of the combined set of mRNAs, proteins, and miRNAs via IPA reveals several networks of potential interest. The primary biological processes (based on Fisher's exact tests for overrepresentation analysis) are LPS/IL1 mediated signaling, IL17A signaling, tight junction signaling, p53 signaling, pathogenesis of multiple sclerosis, etc. (presumably related to angiogenic activity [ Table 1 ]).
discussion
Perfusion MRI is a promising tool that is now being rou tinely used to interrogate tumor behavior, such as inflamma tion and vascularization. It is already being used for treatment monitoring (eg, assessment of changes due to treatment with antiangiogenic therapy). Since it is a much newer tool than conventional MRI, a study of the specific biological pro cesses associated with perfusion imaging is useful to inform the radiologist about what specifically is being assessed using this modality.
Tumor blood volume (rCBV max ) is a measure of total tumor vasculature and angiogenesis. It has been shown to correlate with microvascular density 18 as well as genes related to angiogenesis regulation 19 and hence is a useful prognostic marker. 5, 8 Our analysis reveals the role of several angiogenesisrelated molecules (at the miRNA, mRNA, and protein levels) associated with this vascular parameter. This functional analysis that spans miRNA, mRNA, and protein entities produces several insights that could perhaps clarify the etiology of GBMs as measured via perfusion imaging in addition to possibly generating new hypotheses that could be validated in a laboratory. Specifically, animal models of GBM with overexpressed gene/miRNA levels might inform on the relationships of these molecules with tumorassociated angiogenic activity.
An examination of the IPAderived pathways reveals roles for several pathways involved in tumorigenesis, tumor growth, and angiogenesis -specifically, IL17 signaling is key to tumor survival, inflammation, and angiogenic activity. 20, 21 Further IL1 signaling has a role in tumormediated angio genesis. 22, 23 An examination of the molecular and cellular activities in IPA reveals a role for several tumor hallmarks, such as modulation of tumor morphology, cell proliferation, cell cycle, and apoptosis. Another interesting point is that the context of angiogenesis ties in the observations from our gene set analysis with the pathogenesis of multiple sclerosis, again suggesting a role for angiogenesis modulation. 24, 25 Angiogenesis is one of the key hallmarks of cancer.
26
HER2 signaling and angiogenesis have been shown to be closely linked. 27, 28 The role of EGFR in GBM is well doc umented. 29 Moreover, its role in modulation of invasion, angiogenesis, and metastasis has been reported; specifically, EGFR signaling contributes to angiogenesis via upregulation of MMP levels and cytokines such as VEGFA and IL8.
30
BRCA2 is a tumor suppressor, 31 so it is expected that its level goes down in the more extreme rCBV phenotype (suggest ing a more aggressive disease). However, its exact relation ship with angiogenesis is not clearly characterized, especially in the context of glioma. Several of these proteins have been shown to play a key role in GBM. For example, JNK2 activation correlates strongly with EGFR expression as well as histological grade in GBM.
32 JNK2 has been shown to control cell proliferation and apoptosis and thus been implicated in tumorigenesis. 33, 34 Furthermore, JNK2 has been shown to an upstream regulator of NFAT activity, which is a critical regu lator of angiogenesis. 35, 36 Among the miRNAs listed in Table 2 , miR495 has been shown to inhibit proliferation of GBM cells by downregu lating CDK6, and thus is heavily downregulated in higher grade gliomas.
37 miRNA26a regulates angiogenesis via modulation of the BMP/SMAD1 signaling.
38,39 miR29b suppresses angiogenesis, migration, and invasion by regulat ing MMP2 levels; thus, it is expected that it would be down regulated in the high rCBV max group, suggesting an activation of these tumorigenic hallmarks. miR30d has been shown to modulate tumor cell proliferation, angiogenesis, and meta stasis. 40, 41 Their specific role in glioma needs to be investigated more thoroughly.
conclusions and Future work
This study reveals the utility of integrating genomic data to dissect the molecular programs underlying the vascular phe notype of the tumor, which is assessed with perfusion imag ing. Our hypothesis is that instead of focusing solely on one -omic modality, combining -omic modalities is more likely to illuminate the molecular mechanisms underlying the dis ease processes. Thus, an integration of mRNA, miRNA, and RPPA data permits the combination of multiple layers of biological complexity: transcriptional, posttranscriptional, and signaling, to infer biological mechanisms underlying this hemodynamic characteristic of GBM.
There are several limitations to address in our study. First, this was a retrospective study performed on a publicly available patient subset, consisting of data acquired on multi ple MRI systems with varying protocols. A study that evalu ates the robustness of these integrative molecular programs across scanning protocols, scanner resolutions, and a larger sample size is essential to establishing their biological role. A separate dataset with uniformity of treatment regimen is the next step in validating the biological role of these genomic programs. Furthermore, incorporating molecular markers such as IDH mutation status and molecular subtype in a multivariate regression can help to deconvolve the underlying molecular programs underlying the perfusion phenotype in GBM. Also, the top ranking pathways and molecules identi fied via integrative analysis need to be validated through lab oratory studies, possibly via in vivo mouse models of GBM. Finally, an experimental analysis of drugs targeting these signaling molecules and implicated pathways might permit the examination of novel or rational therapeutic combinations for GBM. Methodologically, this work infers differentially expressed entities from mediandichotomized patient groups from rCBV max . However, examining associated genes/miR NAs/proteins using the original, continuousvalued rCBV max values (via measures such as Spearman and Kendall correla tion) is another possible avenue for examination. Future work Notes: a only the ones that have an experimentally proven relationship of sequence affinity are shown.
b only the ones that have an experimentally proven relationship of sequence affinity are shown.
will also involve the examination of computational features derived from perfusion data [42] [43] [44] and the assessment of molec ular alterations (mRNA, miRNA, and protein) underlying those characteristics. This will permit the molecular exami nation of hemodynamic characteristics other than rCBV, thus illuminating other aspects beyond those routinely obtained in current clinical practice.
